J Bradley Layton, Lauren Peetluk, Hui Lee Wong, Yixin Jiao, Djeneba Audrey Djibo, Christine Bui, Patricia C Lloyd, Joann F Gruber, Michael Miller, Rachel P Ogilvie, Jie Deng, Ron Parambi, Jennifer Song, Lisa B Weatherby, An-Chi Lo, Kathryn Matuska, Michael Wernecke, Tainya C Clarke, Sylvia Cho, Elizabeth J Bell, John D Seeger, Grace Wenya Yang, Dóra Illei, Richard A Forshee, Steven A Anderson, Cheryl N McMahill-Walraven, Yoganand Chillarige, Kandace L Amend, Mary S Anthony, Azadeh Shoaibi
BACKGROUND: Monovalent booster/additional doses of COVID-19 vaccines were first authorized in August 2021 in the United States. We evaluated the real-world effectiveness of receipt of a monovalent booster/additional dose of COVID-19 vaccine compared with receiving a primary vaccine series without a booster/additional dose. METHODS: Cohorts of individuals receiving a COVID-19 booster/additional dose after receipt of a complete primary vaccine series were identified in 2 administrative insurance claims databases (Optum, CVS Health) supplemented with state immunization information system data between August 2021 and March 2022...
January 2024: Vaccine: X